Business
OS Therapies to Spinoff OS Animal Health into Standalone Public Company
Successful preliminary discussion with NYSE representatives and potential investorsOS Therapies shareholders to receive direct equity participation in new listing'Shelter Me: Cancer Pioneers' film featuring canine and human patients treated with OST-HER2 receives Anthem Award in the 'Documentary or Film under Awareness Categories, Health' categoryCompany congratulates Disney (NYSE: DIS) for winning the 2025 Daytime Emmy 'Outstanding Daytime Special' category and Netflix (NYSE: NFLX) for winning.
About this update from Walt Disney Company (the)
[{"type":"list","items":[{"val":[{"type":"text","content":"Successful preliminary discussion with NYSE representatives and potential investors","length":83,"tagName":"p"}]},{"val":[{"type":"text","content":"OS Therapies shareholders to receive direct equity participation in new listing","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"'Shelter Me: Cancer Pioneers' film featuring canine and human patients treated with OST-HER2 receives Anthem Award in the 'Documentary or Film under Awareness Categories, Health' category","length":203,"tagName":"p"}]},{"val":[{"type":"text","content":"Company congratulates Disney (NYSE: DIS) for winning the 2025 Daytime Emmy 'Outstanding Daytime Special' category and Netflix (NYSE: NFLX) for winning 'Outstanding Writing Team for a Daytime Non-Fiction Program' category","length":236,"tagName":"p"}]},{"val":[{"type":"text","content":"Veterinary oncology market is expected to grow from $1.58 billion in 2024 to $4.77 billion in 2034 according to Towards Health","length":126,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":727,"olType":false},{"type":"text","content":"New York, New York--(Newsfile Corp. - November 20, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today announced its intent to spin off OS Animal Health, Inc. (OSAH) into a standalone public company listed on a national stock exchange. OSAH is the Company's wholly owned subsidiary developing OST-HER2 for canine osteosarcoma. The Company expects OSAH to become a standalone public company on a U.S. national stock exchange in the first half of 2026.","length":570,"tagName":"p"},{"type":"text","content":""Having been a part of the effort to improve the standard of care for dogs with osteosarcoma for over a decade, I'm pleased that OS Therapies has made the decision to have the animal health program be housed in a standalone, separately financed venture so that it can receive the attention it deserves," said Edward Robb, DVM, Animal Health Strategic Advisor for OS Therapies. "I will be taking on a key senior management position with OS Animal Health and will be working to help recruit the best leadership in the veterinary space to support a successful commercial launch once t...